TY - JOUR
T1 - Correlation between Her2/neu and p53 expression to therapy response and survival of patients with epithelial ovarian cancer
AU - Hidayat, Y. M.
AU - Andrijono,
AU - Mihardja, S.G.
AU - Siregar, Budiningsih
PY - 2008
Y1 - 2008
N2 - Objective: The purpose of this trials is to know over expression of Her-2/neu and p53 on epithelial ovarian cancer patien with surgical and chemotherapy procedure in RSCM and the relation between histopatology carcinomas grading, chemotherapy response and 1 year, 3 years, 5 years survival rate.Material and methods: Cross sectional method with historical cohort to know about overexpression Her-2/neu and p53 prevalence on epithelial ovarian cancer patien, clinical risk factor, histopatologic carcinomas grading and the relation between risk factors and therapeutic effect and 1 year, 2 years, and 5 years survival rate in RSCM from January 1999 to December 2003.Results: Since January 1998 to 31 December 2003, had been collected 178 epithelial ovarian cancer case as a result from histopatologic examination in Patology Anatomy Department FKUI. From 178 cases we include 34 case that fullfil inclusion criteria (fullfil minimal sample: 30 case). From demographic data analysis the most incidence rate is from average age 45,7 years and the most case come to RSCM on the late stage 64,7% with bad habit type of cell 41,4% (clear cell/small cell, undifferentiated, and adenocarcinoma). From this investigation, survival rate of ovarian cancer patient, survival> 1 year (70,5%), survival > 3 years (47,1%) and survival > 5 years (41,2%), prevalence of overexpression on the subject of investigation is 8,8%, lower than others investigation. Protein gen p53 expression positive (+1,+2,+3 ) is 50% and negative expression is 50%. On correlation expression with various clinical variable, for example type of cell, cell differentiated, stage, chemoterapy respond, length of disease free and survival 1 year, 2 years, and 5 years didn’t have any significance difference, distribution of positive and negative expression of Her-2/neu and p53 almost on average range. There is no significance differences (p > 0,05 ). The relation between clinical variable and chemotherapy response and survival on this trial showed a quite significance differences for example on complete surgery give better survival rate 1 year, 3 years, and 5 years compared with suboptimal citoreduction, had been proved by statistically analysis with correlation coefficient rank spearman rs = 0,450, p = 0,011 (p < 0,005 ).Conclusion: Finds the prevalence of over expression of gen Her- 2/neu in RSCM (+2) 8,8% and the expression of protein gen p53 is 50%. There is no relation between overexpression of protein gen Her-2/neu and p53 with cell differentiation, chemotherapy respond and survival, but there is significance correlation between clinical variable type of surgical procedure, stage, and cell differentiation with chemotherapy response and survival.Keywords: overexpression, Her-2/neu, p53, chemotherapy response, survival.
AB - Objective: The purpose of this trials is to know over expression of Her-2/neu and p53 on epithelial ovarian cancer patien with surgical and chemotherapy procedure in RSCM and the relation between histopatology carcinomas grading, chemotherapy response and 1 year, 3 years, 5 years survival rate.Material and methods: Cross sectional method with historical cohort to know about overexpression Her-2/neu and p53 prevalence on epithelial ovarian cancer patien, clinical risk factor, histopatologic carcinomas grading and the relation between risk factors and therapeutic effect and 1 year, 2 years, and 5 years survival rate in RSCM from January 1999 to December 2003.Results: Since January 1998 to 31 December 2003, had been collected 178 epithelial ovarian cancer case as a result from histopatologic examination in Patology Anatomy Department FKUI. From 178 cases we include 34 case that fullfil inclusion criteria (fullfil minimal sample: 30 case). From demographic data analysis the most incidence rate is from average age 45,7 years and the most case come to RSCM on the late stage 64,7% with bad habit type of cell 41,4% (clear cell/small cell, undifferentiated, and adenocarcinoma). From this investigation, survival rate of ovarian cancer patient, survival> 1 year (70,5%), survival > 3 years (47,1%) and survival > 5 years (41,2%), prevalence of overexpression on the subject of investigation is 8,8%, lower than others investigation. Protein gen p53 expression positive (+1,+2,+3 ) is 50% and negative expression is 50%. On correlation expression with various clinical variable, for example type of cell, cell differentiated, stage, chemoterapy respond, length of disease free and survival 1 year, 2 years, and 5 years didn’t have any significance difference, distribution of positive and negative expression of Her-2/neu and p53 almost on average range. There is no significance differences (p > 0,05 ). The relation between clinical variable and chemotherapy response and survival on this trial showed a quite significance differences for example on complete surgery give better survival rate 1 year, 3 years, and 5 years compared with suboptimal citoreduction, had been proved by statistically analysis with correlation coefficient rank spearman rs = 0,450, p = 0,011 (p < 0,005 ).Conclusion: Finds the prevalence of over expression of gen Her- 2/neu in RSCM (+2) 8,8% and the expression of protein gen p53 is 50%. There is no relation between overexpression of protein gen Her-2/neu and p53 with cell differentiation, chemotherapy respond and survival, but there is significance correlation between clinical variable type of surgical procedure, stage, and cell differentiation with chemotherapy response and survival.Keywords: overexpression, Her-2/neu, p53, chemotherapy response, survival.
UR - http://indonesia.digitaljournals.org/index.php/IJOG/article/view/991
M3 - Article
SN - 2338-6401
VL - 32
JO - Indonesian Journal of Obstetrics and Gynecology
JF - Indonesian Journal of Obstetrics and Gynecology
IS - 4
ER -
